https://vimeo.com/623387429/ebc321e12e
<iframe title="vimeo-player" src="https://player.vimeo.com/video/623387429?h=ebc321e12e" width="640" height="426" frameborder="0" allowfullscreen></iframe>
Primer Blog "específico" de Marketing Farmacéutico para países de habla hispana.
https://vimeo.com/623387429/ebc321e12e
<iframe title="vimeo-player" src="https://player.vimeo.com/video/623387429?h=ebc321e12e" width="640" height="426" frameborder="0" allowfullscreen></iframe>
Pero ¿qué sabemos realmente de esta enfermedad? Más de la mitad de la población sufre de dolores de cabeza, bajo la equivocada idea de que esto es «normal», lo que causa que más del 70 % de las personas con migraña jamás reciban el tratamiento que podría mejorar radicalmente su calidad de vida.
En este libro, Ernesto Bancalari Benavides, neurólogo experto en cefaleas con más de treinta años de experiencia clínica, nos acerca a la verdad sobre esta incomprendida enfermedad, rompe los mitos en torno a ella y brinda útiles consejos para controlarla, tratarla y, además, prevenirla.
La premisa: una vida plena y feliz con migraña es posible.
Dr. Ernesto Bancalari es médico y cirujano por la Universidad Peruana Cayetano Heredia, donde se graduó de neurólogo clínico en 1992. Obtuvo el doctorado en Medicina por la misma universidad en 2004. Actualmente, es miembro de número de la Academia Nacional de Medicina. Ha dedicado los últimos treinta años de su ejercicio profesional al estudio y tratamiento de las cefaleas, y ha compartido su experiencia a través de la docencia en la Universidad Peruana Cayetano HBill Anderson’s mutation
The thoughtshop happened just a few days after Bayer’s CEO Bill Anderson had announced a more than usually radical restructure, which involved not only some significant new appointments but also a pretty drastic delayering. It’s not always easy to see through the corporate PR-speak, but it seems clear that he is trying to accelerate the venerable company’s adaptation to our market’s changing social and technological environment. Frustrated by Bayer’s bureaucracy, Anderson is shrinking the leadership team and central management functions while pushing decision-making down the organisation. In the thoughtshop, this move became a point of discussion. Would it work? What would Charles Darwin predict for Anderson’s chances of success?
Nine brains
Idea vehicles
Metaphors are more than writers’ devices. In science, they are a vehicle for carrying useful ideas from one subject area to another: Think of CRISPR’s molecular scissors and cell factories. They can be stretched too far but, used intelligently, metaphors are very useful. Applied to the question of whether Bayer’s restructure will work, they provide an answer that depends on two contingencies.
_First, octopuses’ distributed brains work because their limb brains have evolved to be extraordinarily good at making sense of their local environment. Each of them processes the information from up to 280 suckers, each of which has 10,000 neurons that feel and taste. _Second, octopuses’ success is also due to coordination between limbs, which work together to push food into their mouths. Subsidiary sensing and central coordination are the two things that make octopuses so intelligent and effective. Without either, these creatures wouldn’t be the doyens of intelligence researchers that they are.
The Leverkusen displacement
As Donald Schön wrote, organisations learn by displacing ideas from one context to their own and, if he’s as smart as I think he is, Anderson will displace cephalopodologists’ ideas into Bayer’s Leverkusen office. He’ll ensure that his distributed decision-makers have the capabilities and resources to make sense of, and react to, their market sub-environment. At the same time, he’ll direct the much-reduced headquarters staff to be conduits and coordinators rather than controllers. Both of these tasks are much easier to write than to do and the success of Bayer’s reorganisation depends on its implementation. Anderson’s octopus move certainly could work, but whether it will or not hinges on another factor, clues to which lie in his public announcement.
Cultural artefacts
Anderson was quoted in the industry media as saying Bayer’s bureaucracy was the problem, not its culture. That suggests a gap in his understanding. Bureaucracy is an artefact of organisational culture, not separate from it. When he complains about small decisions needing multiple signatures, he’s observing a surface indication of a deep-seated culture that, like all organisational cultures, is persistent and pervasive. He can fix all the bureaucratic issues he wants, but if he doesn’t address the implicit values and ‘taken for granted’ assumptions that underlie them, they will come back to hinder even the most distributed intelligence. I’m very fond of Bayer and I really want its octopus move to be successful. That is more likely if Anderson is less complacent about the grand old firm’s culture.
The documentary was released to coincide with Dramamine’s 75th anniversary — which just so happens to be the same year the barf bag debuted.
It explores the extensive archives of three barf bag collectors, delving into how they accumulated their collections and why Dramamine’s continued usage has diminished their importance in the grander scheme of things.
The Last Barf Bag is equal parts bizarre, sincere, funny and poignant. The collectors gleefully expound on the artistic and cultural importance of barf bags, noting how designs and functions differ across airlines and countries. One collector even unfolds a barf bag that found its way onto the Space Shuttle.
You’ll have to allow Klick Health founder, chairman and group CEO Leerom Segal a few moments of boasting when he talks about the company’s “unfair advantage” with AI. After all, AI is based on data. And Klick has been collecting data — lots and lots and lots of data — since Segal, a high-school hacker, founded the company with two colleagues in 1997. How much data does Klick have? Let’s just say it calls just one part of its vast database MedOcean.
The data comes from both internal and external sources. Twenty-four years’ worth of company work data is at the heart of Klick’s internal-use generative AI tool Genome Perspective, which provides a succinct example of how the company approaches AI.
The tool, according to the company’s website, is “the first to be developed by an advertising agency to expedite project planning and increase the efficiency and velocity of delivery to clients.”
“Dum loquimur,
fugerit in vida aetas:
CARPE DIEM
quam minimum credula postero”
“Mientras hablamos,
habrá huido celosa la edad:
goza a bocados del momento,
confía lo menos posible
en el mañana”